DeepMed Research

Idorsia Ltd

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Subsidiary

Employees: -

Market Cap: $464M

Website: http://www.idorsia.com

Clinical Trials

A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ACT-1014-6470 40 mg

First Posted Date: 2021-05-24

Last Posted Date: 2021-11-29

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 16

Registration Number: NCT04899219

Locations: 🇩🇪
APEX GmbH, Munich, Germany

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod

Phase 1

Recruiting

Conditions: Healthy
Hepatic Impairment

Interventions: Drug: Cenerimod

First Posted Date: 2021-03-29

Last Posted Date: 2023-11-03

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 24

Registration Number: NCT04819464

Locations: 🇵🇹
BlueClinical Phase 1 Hospital de Prelado, Porto, Portugal
🇭🇺
CRU Hungary, Kistarcsa, Hungary

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ACT-777991 (SAD)
Drug: ACT-777991 (MAD)
Drug: 14C-ACT-777991 microtracer (MAD - ADME)
Drug: 14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)
Drug: Placebo (SAD)
Drug: Placebo (MAD)
Drug: Microtracer matching placebo (SAD - Absolute Bioavailability)
Drug: Microtracer matching placebo (MAD - ADME)

First Posted Date: 2021-03-15

Last Posted Date: 2022-06-21

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 70

Registration Number: NCT04798209

Locations: 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands

Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder

Phase 2

Completed

Conditions: Binge-Eating Disorder

Interventions: Drug: ACT-539313
Drug: Placebo

First Posted Date: 2021-02-15

Last Posted Date: 2023-03-31

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 136

Registration Number: NCT04753164

Locations: 🇺🇸
NeuorTrials Research Inc, Atlanta, Georgia, United States
🇺🇸
Collaborative Neuroscience Network (CNS), Garden Grove, California, United States
🇺🇸
Wr-Pri, Llc, Encino, California, United States

and more 27 locations

A Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ACT-1014-6470
Drug: Placebo

First Posted Date: 2020-10-29

Last Posted Date: 2021-10-15

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 46

Registration Number: NCT04608513

Locations: 🇩🇪
Parexel International GmbH Klinikum Westend, Berlin, Germany

A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Selatogrel

First Posted Date: 2020-09-21

Last Posted Date: 2022-11-16

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 24

Registration Number: NCT04557280

Locations: 🇺🇸
Altasciences Clinical Kansas, Inc, Overland Park, Kansas, United States

Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2

Completed

Conditions: Sandhoff Disease
Tay-Sachs Disease
GM1 Gangliosidosis
GM2 Gangliosidosis
Gaucher Disease, Type 2
AB Variant Gangliosidosis GM2

First Posted Date: 2020-07-14

Last Posted Date: 2021-11-08

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 226

Registration Number: NCT04470713

Locations: 🇺🇸
Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇧🇷
Hospital de Clínicas de Porto Alegre - HCPA, Porto Alegre, Brazil

and more 14 locations

A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: ACT-541478 high or low dose (or placebo)
Drug: ACT-541478 100 mg
Drug: ACT-541478 300 mg
Drug: ACT-541478 30 mg
Drug: ACT-541478 10 mg
Drug: ACT-541478 1000 mg
Drug: ACT-541478 dose E1
Drug: Matching placebo

First Posted Date: 2020-06-30

Last Posted Date: 2021-07-09

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 56

Registration Number: NCT04452006

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany

The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics

Phase 1

Completed

Conditions: Healthy Subjects
Hepatic Impairment

Interventions: Drug: Selatogrel

First Posted Date: 2020-05-29

Last Posted Date: 2022-11-16

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 24

Registration Number: NCT04406896

Locations: 🇩🇪
CRS Clinical Research Services, Kiel, Germany

A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Daridorexant
Drug: Efavirenz
Drug: Famotidine

First Posted Date: 2020-05-15

Last Posted Date: 2020-09-16

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 24

Registration Number: NCT04390334

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy